期刊文献+

LC-MS/MS法测定人血浆中甲磺酸雷沙吉兰的浓度及其药动学研究 被引量:1

Determination of Rasagiline Mesilate in Human Plasma by LC-MS/MS and Study on Its Pharmacokinetics
原文传递
导出
摘要 目的:建立以高效液相色谱电喷雾串联质谱(LC-MS/MS)法测定人血浆中甲磺酸雷沙吉兰浓度的方法,并研究其在健康人体内的药动学。方法:以盐酸罂粟碱为内标,血浆样品经液-液萃取后,采用Intersil ODS-3进行分离,通过三重四级杆串联质谱仪,以选择性反应监测(SRM)方式进行测定。结果:甲磺酸雷沙吉兰血药浓度在0.010~40ng·mL-1范围内线性关系良好(r=0.9998);方法回收率为90.55%~101.57%,日内、日间RSD均≤15%。结论:本方法快速、准确、灵敏,适用于甲磺酸雷沙吉兰的人体药动学研究。 OBJECTIVE:To establish an LC-MS/MS method for the determination of rasagiline mesilate in human plasma and study its pharmacokinetics in healthy subjects.METHODS:Plasma samples were extracted using liquid-liquid extraction with cardoverine as internal standard then separated on Intersil ODS-3 column.The content of rasagiline mesilate in human plasma was detected by selective reaction monitoring(SRM)on a triple quadrupoles tandem mass spectrometer.RESULTS:The linear range of rasagiline mesilate was 0.010~40 ng·mL-(1r=0.999 8)with an recovery rate of 90.55%~101.57%.The RSD of inter-day and intra-day were all lower than 15%.CONCLUSION:The method is rapid,accurate and sensitive for pharmacokinetic study of rasagiline mesilate.
出处 《中国药房》 CAS CSCD 北大核心 2010年第38期3598-3600,共3页 China Pharmacy
关键词 高效液相色谱电喷雾串联质谱法 甲磺酸雷沙吉兰 药动学 血药浓度 LC-MS/MS Rasagiline mesilate Pharmacokinetics Plasma concentration
  • 相关文献

参考文献3

二级参考文献9

  • 1刘廷辉.新型抗帕金森病药——雷沙吉兰[J].中国药学杂志,2006,41(11):877-878. 被引量:7
  • 2中华人民共和国国家药典委员会编.中国药典(2000年版二部)[Z].北京:化学工业出版社,2000. 被引量:1
  • 3CHEN J J,SWOPE D M.Clinical pharmacology of rasagiline:a novel,second-generation propargylamine for the treatment of Parkinson disease[J].J Clin Pharmacol,2005,45 (8):878-894. 被引量:1
  • 4YOUDIM M B,MARUYAMA W,NAOI M.Neuropharmacological,neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug,rasagiline[J].Drugs Today,2005,41 (6):369-391. 被引量:1
  • 5MAMDEL S,WEINREB O,AMIT T,et al.Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives[J].Brain Res Rev,2005,48(2):379-387. 被引量:1
  • 6THEBAULT J J,GUILLAUME M,LEVU R.Tolerability,safety,pharmacodynamics,and pharmacokinetics of rasagiline:a potent,selective,and irreversible monoamine oxidase type B inhibitor[J].Pharmacotherapy,2004,24(10):1295-1305. 被引量:1
  • 7Parkinson Study Group.A controlled,randomized,delayed-start study of rasagiline in early Parkinson disease[J].Arch Neurol,2004,61(4):561-566. 被引量:1
  • 8RASCPM O,BROOKS D J,MELAMED E,et al.Rasagiline as an adjunct to levodopa in patients with Parkinson' s disease and motor fluctuations (LARGO,Lasting effect in Adjunct therapy with Rasagiline Given Once daily,study):a randomised,double-blind,parallelgroup trial[J].Lancet,2005,365(9 463):914-916. 被引量:1
  • 9SODDOQIO M A,PLOSKER G L.Rasagiline[J].Drugs Aging,2005,22(1):83-91. 被引量:1

共引文献6

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部